Last update 21 Nov 2024

Guanoxan Sulfate

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Guanoxan, Guanoxan sulfate (USAN)

+ [2]

Target

adrenergic receptor

Mechanism

adrenergic receptor agonists(Adrenergic receptors agonists)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC20H28N6O8S

InChIKeyNSGHAKPGHCNTPS-UHFFFAOYSA-N

CAS Registry5714-04-5

100 Clinical Results associated with Guanoxan Sulfate

100 Translational Medicine associated with Guanoxan Sulfate

100 Patents (Medical) associated with Guanoxan Sulfate

Literatures (Medical) associated with Guanoxan Sulfate

01 Sep 2001·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

N-Hydroxyl derivatives of guanidine based drugs as enzymatic NO donors

Q4 · MEDICINE

Article

Author: Xiaoping Tang ; James J Galligan ; Zhongling Zheng ; Xinchao Chen ; Ming Xian ; Xiaopeng Li ; Peng G Wang ; David L Kreulen

Recent research suggests that NO may play a role in the physiological effects of some guanidine-containing drugs. In this report, three guanidine-containing drugs (guanadrel, guanoxan, and guanethidine) together with their N-hydroxyl derivatives were synthesized and their NO-releasing abilities catalyzed by nitric oxide synthases (NOSs) and horseradish peroxidase were evaluated. The guanidine containing compounds could not release NO in the presence of NOS or peroxidase. The corresponding N-hydroxyl compounds exhibited weak NO-releasing ability under the catalyzed of NOS and good NO-releasing ability under the oxidation by horseradish peroxidase in the presence of H(2)O(2). These compounds also displayed vasodilatory activity.

01 Sep 1994·European Journal of PharmacologyQ3 · MEDICINE

Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors

Q3 · MEDICINE

Article

Author: Kulkarni, Rohit N. ; Olmos, Gabriel ; Haque, Munirul ; MacDermot, John

The effect on insulin release of efaroxan, an alpha 2-adrenoceptor antagonist and a highly potent drug at imidazoline I1 receptors, and the effects of seven other imidazoline compounds selective for the imidazoline I1 or I2 receptors, were studied in the rat insulinoma cell line RIN-5AH. The cells released insulin in response to glucose (0.3-10 mM), and efaroxan (100 microM) potentiated glucose-induced insulin release. (-)-Adrenaline completely displaced the binding of [125I]p-iodoclonidine to membranes of RIN-5AH cells, indicating that these cells do not express imidazoline I1 receptors. Cirazoline and idazoxan (100 microM), both highly potent drugs at imidazoline I2 receptors, and the guanidines guanoxan and amiloride (200 microM), also promoted insulin release from RIN-5AH cells. Irreversible blockade of imidazoline I2 receptors with 10 microM clorgyline did not prevent the stimulatory effects of cirazoline or idazoxan; however, these compounds completely reversed the inhibition by diazoxide (250 microM), an opener of ATP-dependent K+ channels (K+ATP channels), of glucose-induced insulin release. These data indicate that the imidazoline/guanidine compounds promote insulin release from RIN-5AH cells, by interacting with a novel binding site related to K+ATP channels that does not represent any of the known imidazoline I1 or I2 receptors.

01 Aug 1993·Archives of Biochemistry and BiophysicsQ3 · BIOLOGY

Competitive Inhibition of Xanthine Oxidase by Guanidinium: Dependence upon Monovalent Anions and Effects on Production of Superoxide

Q3 · BIOLOGY

Article

Author: I. Fridovich ; A. Hausladen

Guanidinium chloride inhibits xanthine oxidase competitively with respect to xanthine. Although previously attributed solely to the guanidinium cation, it is now apparent that this inhibition owes much to the counter anion. Thus KCl or KBr, which were not themselves inhibitory, markedly increased the inhibitory potency of guanidinium sulfate. Weak binding of the guanidinium cation evidently creates a binding site for a monovalent anion, whose subsequent binding then stabilizes the binding of the guanidinium. In effect the ion pair is bound to the catalytic center. The proportion of univalent reduction of dioxygen by xanthine oxidase, at fixed concentrations of xanthine and dioxygen and at fixed pH, can be markedly increased by addition of a competitive inhibitor such as guanidinium bromide.

100 Deals associated with Guanoxan Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D04399	-	C02CC03	DB13211

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis